Autolus Therapeutics PLC AUTL
We take great care to ensure that the data presented and summarized in this overview for Autolus Therapeutics plc is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding AUTL
View all-
Wellington Management Group LLP Boston, MA27.1MShares$58.4 Million0.01% of portfolio
-
Blackstone Inc New York, NY20.5MShares$44 Million0.22% of portfolio
-
Mak Capital One LLC New York, NY17MShares$36.5 Million5.54% of portfolio
-
Deep Track Capital, LP Greenwich, CT16.9MShares$36.2 Million1.36% of portfolio
-
Syncona Portfolio LTD Guernsey, Channel Islands, X016.6MShares$35.8 Million98.24% of portfolio
-
Armistice Capital, LLC New York, NY12MShares$25.8 Million0.48% of portfolio
-
Tfg Asset Management Gp LTD Grand Cayman, E99.5MShares$20.4 Million5.47% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA4.62MShares$9.94 Million0.56% of portfolio
-
Black Rock Inc. New York, NY4.44MShares$9.54 Million0.0% of portfolio
-
Schroder Investment Management Group London, X03.61MShares$7.76 Million0.01% of portfolio
Latest Institutional Activity in AUTL
Top Purchases
Top Sells
About AUTL
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma. It also focuses on developing AUTO5, a hematological product candidate, which is in preclinical development. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.
Insider Transactions at AUTL
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|